




# PHARMACEUTICAL 2020

Bellerophon Therapeutics Inc.  
Rank 284 of 358





RealRate

# PHARMACEUTICAL 2020

## Bellerophon Therapeutics Inc. Rank 284 of 358

The relative strengths and weaknesses of Bellerophon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Bellerophon Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is -63%, being 99% points below the market average of 36%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 10,382            |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 7,584             |
| Liabilities, Non-Current                    | 1,659             |
| Other Assets                                | 2,410             |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | -3,783            |
| Other Liabilities                           | 274               |
| Other Net Income                            | 397               |
| Other Revenues                              | 0                 |
| Property and Equipment                      | 316               |
| Research and Development                    | 11,032            |
| Selling, General and Administrative Expense | 6,441             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 13,108            |
| Liabilities              | 9,517             |
| Expenses                 | 13,690            |
| Revenues                 | 0                 |
| Stockholders Equity      | 3,591             |
| Net Income               | -13,293           |
| Comprehensive Net Income | -13,293           |
| Economic Capital Ratio   | -63%              |